All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention ALS (Amyotrophic Lateral Sclerosis), the most common co-covered peer. The tracked stories average 2 original sources each. Speech-generating device appears in 1 tracked Biotech story from August 7, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Speech-generating device
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention ALS (Amyotrophic Lateral Sclerosis), the most common co-covered peer. The tracked stories average 2 original sources each. Speech-generating device appears in 1 tracked Biotech story from August 7, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Speech-generating device. Shared-story counts are live from our verified record — not editorial picks.
The devastating speed of Chris Johnson’s sporadic ALS—from an elite athlete to eye-controlled communication in a year—exposes the profound unmet need in neurodegenerative drug development. With current therapies offering only months of survival benefit, the biopharma sector faces immense pressure to deliver disease-modifying treatments.